Key result
In patients with CKD, higher plasma MCP-1 levels are associated with an additional eGFR decline of approximately 1.0 mL/min/1.73 m² per year compared to the lowest MCP-1 group.
Why the study?
Monocyte chemoattractant protein-1 is implicated in the pathogenesis of chronic kidney disease, but its clinical significance in CKD remains unclear.
Do higher plasma MCP-1 levels predict kidney and cardiovascular outcomes in patients with advanced chronic kidney disease?
Do higher plasma MCP-1 levels predict kidney and cardiovascular outcomes in patients with advanced chronic kidney disease?
Answers are grounded in this paper and cite their sources.
In patients with advanced CKD, higher plasma MCP-1 levels are associated with a more rapid decline in kidney function but do not independently predict composite kidney failure, cardiovascular outcomes, or mortality.
Background Monocyte chemoattractant protein-1 (MCP-1) has been implicated in the pathogenesis of chronic kidney disease (CKD); however, its clinical significance in CKD remains unclear. This study investigated the association between plasma MCP-1 levels and kidney and cardiovascular outcomes in patients with CKD. Methods This multicenter, prospective, observational analysis used data from the BRIGHTEN study. Participants with anemia and CKD (eGFR < 60 mL/min/1.73 m 2 ) were classified into four groups based on quartiles of their baseline plasma MCP-1 levels. The primary outcomes included kidney outcomes (a composite of initiation of maintenance dialysis, kidney transplantation, 50% decline in eGFR, or eGFR ≤ 6 mL/min/1.73 m 2 ), the annual rate of eGFR decline, cardiovascular outcomes, and all-cause mortality. Associations were assessed using Cox proportional hazard and linear mixed-effects models. Results This study included 1,447 participants with advanced CKD (median eGFR 17.9 mL/min/1.73 m²). The group with the lowest MCP-1 level (< 324.5 pg/mL) had the highest baseline eGFR. In the univariable analyses, higher MCP-1 levels were associated with an increased risk of kidney and cardiovascular outcomes (log-rank p < 0.01 and p = 0.03, respectively), although these associations were not significant after multivariable adjustment. Analysis of the annual eGFR decline using a multivariable linear mixed-effects model revealed that higher MCP-1 levels were associated with an additional eGFR decline of approximately 1.0 mL/min/1.73 m 2 per year compared to the lowest MCP-1 group. MCP-1 levels were not associated with mortality. Conclusions In patients with CKD, higher plasma MCP-1 levels are associated with a more rapid decline in kidney function but not with the composite outcome of kidney failure. MCP-1 was not associated with cardiovascular outcomes or mortality in this population cohort.
No takes yet. Share an insight, caveat, or question.
Toyama et al. (2025) studied this question. In patients with CKD, higher plasma MCP-1 levels are associated with an additional eGFR decline of approximately 1.0 mL/min/1.73 m² per year compared to the lowest MCP-1 group.
Synapse has enriched 10 related papers. Consider them for comparative context: